The estimated Net Worth of David V Elkins is at least $32.1 millió dollars as of 10 March 2024. Mr. Elkins owns over 64,326 units of Bristol-Myers Squibb Co stock worth over $10,938,143 and over the last 15 years he sold BMY stock worth over $16,766,543. In addition, he makes $4,371,550 as Executive Vice President and Chief Financial Officer Member of the Leadership Team at Bristol-Myers Squibb Co.
Sign up
Mr. Elkins BMY stock SEC Form 4 insiders trading
David has made over 22 trades of the Bristol-Myers Squibb Co stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 64,326 units of BMY stock worth $3,125,600 on 10 March 2024.
The largest trade he's ever made was selling 133,951 units of Bristol-Myers Squibb Co stock on 13 September 2022 worth over $9,550,706. On average, David trades about 19,814 units every 112 days since 2009. As of 10 March 2024 he still owns at least 225,111 units of Bristol-Myers Squibb Co stock.
You can see the complete history of Mr. Elkins stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Elkins biography
David V. Elkins serves as Executive Vice President and Chief Financial Officer Member of the Leadership Team of the Company. 2014 to 2017 – Group Vice President and Chief Financial Officer, Consumer and Consumer Medicines, Johnson & Johnson 2017 to 2018 – Worldwide Vice President and Chief Financial Officer, Consumer Products, Medical Development and Corporate Functions, Johnson & Johnson 2018 to 2019 – Chief Financial Officer, Celgene 2019 to present – Executive Vice President and Chief Financial Officer
What is the salary of David Elkins?
As the Executive Vice President and Chief Financial Officer Member of the Leadership Team of Bristol-Myers Squibb Co, the total compensation of David Elkins at Bristol-Myers Squibb Co is $4,371,550. There are 4 executives at Bristol-Myers Squibb Co getting paid more, with Giovanni Caforio having the highest compensation of $18,767,300.
How old is David Elkins?
David Elkins is 51, he's been the Executive Vice President and Chief Financial Officer Member of the Leadership Team of Bristol-Myers Squibb Co since 2019. There are 30 older and 4 younger executives at Bristol-Myers Squibb Co. The oldest executive at Bristol-Myers Squibb Co. is Vicki Sato, 71, who is the Lead Independent Director.
What's David Elkins's mailing address?
David's mailing address filed with the SEC is BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NJ, 08543.
Insiders trading at Bristol-Myers Squibb Co
Over the last 17 years, insiders at Bristol-Myers Squibb Co have traded over $318,151,721 worth of Bristol-Myers Squibb Co stock and bought 211,503 units worth $6,601,565 . The most active insiders traders include Lamberto Andreotti, James M Cornelius és Giovanni Caforio. On average, Bristol-Myers Squibb Co executives and independent directors trade stock every 8 days with the average trade being worth of $1,682,720. The most recent stock trade was executed by Cari Gallman on 1 August 2024, trading 1,061 units of BMY stock currently worth $51,554.
What does Bristol-Myers Squibb Co do?
The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.
What does Bristol-Myers Squibb Co's logo look like?
Complete history of Mr. Elkins stock trades at Becton Dickinson & Co, Bristol-Myers Squibb Co és Tapestry Inc
Bristol-Myers Squibb Co executives and stock owners
Bristol-Myers Squibb Co executives and other stock owners filed with the SEC include:
-
Giovanni Caforio,
Chairman of the Board, Chief Executive Officer -
Sandra Leung,
Executive Vice President, General Counsel -
Dr. Giovanni Caforio M.D.,
Chairman & CEO -
Christopher Boerner,
Executive Vice President and Chief Commercial Officer -
David Elkins,
Executive Vice President and Chief Financial Officer Member of the Leadership Team -
Rupert Vessey,
Executive Vice President, Research and Early Development Member of the Leadership Team -
Louis Schmukler,
Executive Vice President, President - Global Product Development and Supply -
David V. Elkins,
Exec. VP & CFO -
Rupert Vessey BCH, BM, DPHIL, M.A.,
Exec. VP and Pres of Research & Early Devel. -
Sandra Leung Esq.,
Exec. VP & Gen. Counsel -
Dr. Christopher S. Boerner,
Exec. VP & Chief Commercialization Officer -
Vicki Sato,
Lead Independent Director -
Matthew Emmens,
Independent Director -
Peter Arduini,
Independent Director -
Dinesh Paliwal,
Independent Director -
Theodore Samuels,
Independent Director -
Karen Vousden,
Independent Director -
Robert Bertolini,
Independent Director -
Gerald Storch,
Independent Director -
Phyllis Yale,
Independent Director -
Julia Haller,
Independent Director -
Michael Bonney,
Independent Director -
Derica Rice,
Independent Director -
Paula Price,
Independent Director -
Tim Power,
Vice President of Investor Relations -
Joseph Eid,
Senior Vice President and Head of Global Medical Affairs Member of the Leadership Team -
Karen Santiago,
Senior Vice President, Corporate Controller -
Adam Dubow,
Senior Vice President, Chief Compliance Officer and Ethics Officer -
Paul von Autenried,
Chief Information Officer, Senior Vice President -
Elizabeth Mily,
Executive Vice President - Strategy & Business Development -
Kathryn Metcalfe,
Executive Vice President - Corporate Affairs Member of the Leadership Team -
Samit Hirawat,
Executive Vice President, Chief Medical Officer, Global Drug Development Member of the Leadership Team -
Nadim Ahmed,
Executive Vice President and President - Hematology -
John Elicker,
Executive Vice President of Investor Relations -
Ann Judge,
Chief Human Resource Officer, Senior Vice President Member of the Leadership Team -
Ann M. Powell Judge,
Exec. VP & Chief HR Officer -
Adam Dubow,
Sr. VP, Chief Compliance & Ethics Officer -
Timothy Power,
VP & Head of Investor Relations -
Paul von Autenried,
Exec. VP & Chief Information Officer -
Greg Meyers,
Exec. VP and Chief Digital & Technology Officer -
Jose Baselga,
Director -
Alan J Lacy,
Director -
Joseph C Caldarella,
VP & Financial Controller -
Anne Nielsen,
Chief Compliance & Ethics Off -
Laurie H M.D. Glimcher,
Director -
Michael Grobstein,
Director -
Togo D Jr West,
Director -
Emmanuel Blin,
SVP, Head of Commercialization -
Francis M Cuss,
SVP Dscvry & Exp Clinl Resrch -
Murdo Gordon,
SVP, Head of Worldwide Markets -
Thomas J. Jr. Lynch,
Director -
Karin Shanahan,
EVP, Glob. Prod. Dev. & Supply -
Lynelle Hoch,
President, Cell Therapy Org. -
Phil M Holzer,
SVP and Controller -
Ahn Amanda Poole,
EVP, Chief Human Resources -
Samuel J Moed,
SVP, Strat Plan & Analysis -
Michelle Weese,
EVP, Corporate Affairs -
Paul Biondi,
SVP, Head of Strategy & BD -
Charles A Bancroft,
EVP, Head of Integration -
Ann Powell,
EVP, Chief Human Resources -
Frances K Heller,
SVP, Business Development -
Brian Daniels,
SVP Global Development -
Elliot Sigal,
EVP, CSO & President R&D -
Beatrice J Cazala,
SVP Comm Ops & Pres GC Euro EM -
Robert T Zito,
SVP & Chief Comm Officer -
Jeremy M Levin,
SVP Strat Transactions -
R Sanders Williams,
Director -
Anthony C Hooper,
President US Pharmaceuticals -
Louis J Freeh,
Director -
Anthony A Mcbride,
SVP Human Resources -
De Notaristefani Carlo,
President, Tech Ops -
Leif Johansson,
Director -
John E Celentano,
SVP Strat & Productivity Trans -
Jean Marc Huet,
SVP & CFO -
James M Cornelius,
Chairman & CEO -
Lewis B Campbell,
Director -
Medina Manuel Hidalgo,
Director -
Benjamin Hickey,
President, RayzeBio Org. -
Gregory Scott Meyers,
EVP, Chief Digital & Tech Off. -
Sharon Greenlees,
SVP & Controller -
Deepak Bhatt,
Director -
Michael R. Mc Mullen,
Director -
Adam Lenkowsky,
EVP, Chief Commercial Officer -
Robert M Plenge,
EVP, Chief Research Officer -
Cari Gallman,
EVP, Corporate Affairs